There are many kidney diseases that might be addressed by gene therapy. However, gene delivery to kidney cells is inefficient. This is due, in part, to the fact that the kidney excludes molecules above 50 kDa and that most gene delivery vectors are megaDaltons in mass. We compared the ability of adeno-associated virus (AAV), adenovirus (Ad), and lentiviral (LV) vectors to deliver genes to renal cells. When vectors were delivered by the intravenous (IV) route in mice, weak luciferase activity was observed in the kidney with substantially more in the liver. When gene delivery was observed in the kidney, expression was primarily in the glomerulus. To avoid these limitations, vectors were injected directly into the kidney by retrograde ureteral (RU) and subcapsular (SC) injections in mice. Small AAV vectors transduced the kidney, but also leaked from the organ and mediated higher levels of transduction in off-target tissues. Comparison of AAV2, 6.2, 8, and rh10 vectors by direct kidney injection demonstrated highest delivery by AAV6.2 and 8. Larger Ad and LV vectors transduced kidney cells and mediated less off-target tissue transduction. These data demonstrate the utility of direct kidney injections to circumvent the kidney size exclusion barrier. They also identify the effects of vector size on on-target and off-target transduction. This lays the foundation for the use of different vector platforms for gene therapy of diverse kidney diseases.
Get full access to this article
View all access options for this article.
References
1.
HillNR, FatobaST, OkeJL, et al.Global prevalence of chronic kidney disease—a systematic review and meta-analysis. PLoS One, 2016; 11:e0158765.
BoronWF, BoulpaepEL. Glomerular filtration and renal blood flow. In: Medical Physiology. Philadelphia, PA: Elsevier, 2017:739.e732–753.e732.
5.
ItoK, ChenJ, KhodadadianJJ, et al.Adeno-associated viral vector transduction of green fluorescent protein in kidney: effect of unilateral ureteric obstruction. BJU Int, 2008; 101:376–381.
6.
ChungDC, FogelgrenB, ParkKM, et al.Adeno-associated virus-mediated gene transfer to renal tubule cells via a retrograde ureteral approach. Nephron Extra, 2011; 1:217–223.
7.
KonkalmattPR, AsicoLD, ZhangY, et al.Renal rescue of dopamine D2 receptor function reverses renal injury and high blood pressure. JCI Insight, 2016; 1:pii: e85888.
8.
WatanabeS, OgasawaraT, TamuraY, et al.Targeting gene expression to specific cells of kidney tubules in vivo, using adenoviral promoter fragments. PLoS One, 2017; 12:e0168638.
9.
WoodardLE, ChengJ, WelchRC, et al.Kidney-specific transposon-mediated gene transfer in vivo. Sci Rep, 2017; 7:44904.
10.
AsicoLD, CuevasS, MaX, et al.Nephron segment-specific gene expression using AAV vectors. Biochem Biophys Res Commun, 2018; 497:19–24.
11.
HillestadML, GuenzelAJ, NathKA, et al.A vector-host system to fingerprint virus tropism. Hum Gene Ther, 2012; 23:1116–1126.
12.
LieberA, HeCY, MeuseL, et al.The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol, 1997; 71:8798–8807.
13.
WorgallS, WolffG, Falck-PedersenE, et al.Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther, 1997; 8:37–44.
14.
LivetJ, WeissmanTA, KangH, et al.Transgenic strategies for combinatorial expression of fluorescent proteins in the nervous system. Nature, 2007; 450:56–62.
15.
CaiD, CohenKB, LuoT, et al.Improved tools for the Brainbow toolbox. Nat Methods, 2013; 10:540–547.
16.
ShaoX, SomloS, IgarashiP. Epithelial-specific Cre/lox recombination in the developing kidney and genitourinary tract. J Am Soc Nephrol, 2002; 13:1837–1846.
17.
InagakiK, FuessS, StormTA, et al.Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther, 2006; 14:45–53.
18.
SaraivaJ, NobreRJ, Pereira de AlmeidaL. Gene therapy for the CNS using AAVs: the impact of systemic delivery by AAV9. J Control Release, 2016; 241:94–109.
19.
LangJF, ToulminSA, BridaKL, et al.Standard screening methods underreport AAV-mediated transduction and gene editing. Nat Commun, 2019; 10:3415.
20.
KruegelJ, RubelD, GrossO. Alport syndrome—insights from basic and clinical research. Nat Rev Nephrol, 2013; 9:170–178.
21.
MoullierP, FriedlanderG, CaliseD, et al.Adenoviral-mediated gene transfer to renal tubular cells in vivo. Kidney Int, 1994; 45:1220–1225.
22.
McDonaldGA, ZhuG, LiY, et al.Efficient adenoviral gene transfer to kidney cortical vasculature utilizing a fiber modified vector. J Gene Med, 1999; 1:103–110.
23.
ChenS, AgarwalA, GlushakovaOY, et al.Gene delivery in renal tubular epithelial cells using recombinant adeno-associated viral vectors. J Am Soc Nephrol, 2003; 14:947–958.
24.
TakedaS, TakahashiM, MizukamiH, et al.Successful gene transfer using adeno-associated virus vectors into the kidney: comparison among adeno-associated virus serotype 1–5 vectors in vitro and in vivo. Nephron Exp Nephrol, 2004; 96:e119–e126.
25.
ShenX, XuY, BaiZ, et al.Transparenchymal renal pelvis injection of recombinant adeno-associated virus serotype 9 vectors is a practical approach for gene delivery in the kidney. Hum Gene Ther Methods, 2018; 29:251–258.
26.
RoccaCJ, UrSN, HarrisonF, et al.rAAV9 combined with renal vein injection is optimal for kidney-targeted gene delivery: conclusion of a comparative study. Gene Ther, 2014; 21:618–628.
27.
RoccaCJ, CherquiS. Gene transfer to mouse kidney in vivo. Methods Mol Biol, 2019; 1937:227–234.
28.
KhareR, ChenCY, WeaverEA, et al.Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther, 2011; 11:241–258.
29.
CroninJ, ZhangXY, ReiserJ. Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther, 2005; 5:387–398.
30.
HofmeisterAF, KomhoffM, WeberS, et al.Disease modeling in genetic kidney diseases: mice. Cell Tissue Res, 2017; 369:159–170.
31.
VarnavskiAN, ZhangY, SchnellM, et al.Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity. J Virol, 2002; 76:5711–5719.
32.
RaperSE, ChirmuleN, LeeFS, et al.Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab, 2003; 80:148–158.
33.
VarnavskiAN, CalcedoR, BoveM, et al.Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice. Gene Ther, 2005; 12:427–436.
34.
DonsanteA, MillerDG, LiY, et al.AAV vector integration sites in mouse hepatocellular carcinoma. Science, 2007; 317:477.
35.
ChandlerRJ, LaFaveMC, VarshneyGK, et al.Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Invest, 2015; 125:870–880.
NaultJC, DattaS, ImbeaudS, et al.Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet, 2015; 47:1187–1193.
38.
BernsKI, ByrneBJ, FlotteTR, et al.Adeno-associated virus type 2 and hepatocellular carcinoma?. Hum Gene Ther, 2015; 26:779–781.
39.
HindererC, KatzN, BuzaEL, et al.Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum Gene Ther, 2018; 29:285–298.
40.
TanguyY, BiferiMG, BesseA, et al.Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice. Front Mol Neurosci, 2015; 8:36.
41.
WangL, BellP, SomanathanS, et al.Comparative study of liver gene transfer with AAV vectors based on natural and engineered AAV capsids. Mol Ther, 2015; 23:1877–1887.
42.
HocquemillerM, GierschL, AudrainM, et al.Adeno-associated virus-based gene therapy for CNS diseases. Hum Gene Ther, 2016; 27:478–496.
43.
PerdominiM, Dos SantosC, GoumeauxC, et al.An AAVrh10-CAG-CYP21-HA vector allows persistent correction of 21-hydroxylase deficiency in a Cyp21(-/-) mouse model. Gene Ther, 2017; 24:275–281.
44.
GreigJA, NordinJML, WhiteJW, et al.Optimized adeno-associated viral-mediated human factor VIII gene therapy in Cynomolgus macaques. Hum Gene Ther, 2018 [Epub ahead of print]; DOI: 10.1089/hum.2018.080.
45.
Nakamura-TakahashiA, MiyakeK, WatanabeA, et al.Treatment of hypophosphatasia by muscle-directed expression of bone-targeted alkaline phosphatase via self-complementary AAV8 vector. Mol Ther Methods Clin Dev, 2016; 3:15059.
46.
ShaoX, JohnsonJE, RichardsonJA, et al.A minimal Ksp-cadherin promoter linked to a green fluorescent protein reporter gene exhibits tissue-specific expression in the developing kidney and genitourinary tract. J Am Soc Nephrol, 2002; 13:1824–1836.
47.
MunchRC, MuhlebachMD, SchaserT, et al.DARPins: an efficient targeting domain for lentiviral vectors. Mol Ther, 2011; 19:686–693.
48.
DenbyL, WorkLM, SeggernDJ, et al.Development of renal-targeted vectors through combined in vivo phage display and capsid engineering of adenoviral fibers from serotype 19p. Mol Ther, 2007; 15:1647–1654.
49.
DiaconuI, DenbyL, PesonenS, et al.Serotype chimeric and fiber-mutated adenovirus Ad5/19p-HIT for targeting renal cancer and untargeting the liver. Hum Gene Ther, 2009; 20:611–620.
50.
YangL, LiJ, XiaoX. Directed evolution of adeno-associated virus (AAV) as vector for muscle gene therapy. Methods Mol Biol, 2011; 709:127–139.
51.
ShashkovaEV, MaySM, DoroninK, et al.Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus. Mol Ther, 2009; 17:2121–2130.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
